Chemours Co. logo

Chemours Co. (CC)

Market Closed
3 Jun, 20:00
NYSE NYSE
$
22. 61
-0.64
-2.75%
$
3.42B Market Cap
- P/E Ratio
1% Div Yield
1,508,991 Volume
- Eps
$ 23.25
Previous Close
Add Transaction
Day Range
22.6 23.37
Year Range
9.94 28.67
Want to track CC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Chemours (CC) Q1 Earnings Miss Estimates

Chemours (CC) Q1 Earnings Miss Estimates

Chemours (CC) came out with quarterly earnings of $0.13 per share, missing the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.32 per share a year ago.

Zacks | 1 year ago
Analysts Estimate Chemours (CC) to Report a Decline in Earnings: What to Look Out for

Analysts Estimate Chemours (CC) to Report a Decline in Earnings: What to Look Out for

Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 year ago
Why Is Chemours (CC) Down 14% Since Last Earnings Report?

Why Is Chemours (CC) Down 14% Since Last Earnings Report?

Chemours (CC) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 year ago
Chemours Forms Partnership With Energy Fuels to Establish Supply Chain

Chemours Forms Partnership With Energy Fuels to Establish Supply Chain

CC & Energy Fuels team up to expand rare earth and critical mineral supply chains in the U.S. domestic market.

Zacks | 1 year ago
Chemours, NTT DATA & Hibiya Engineering Join Forces for Product Trial

Chemours, NTT DATA & Hibiya Engineering Join Forces for Product Trial

CC partners with industry leaders to address the data center cooling gap by conducting Opteon 2P50 product trials.

Zacks | 1 year ago
Chemours' Earnings Outpace Estimates, Revenues Miss in Q4

Chemours' Earnings Outpace Estimates, Revenues Miss in Q4

CC's sales fall modestly as a drop in pricing is largely offset by a gain in volume, while the currency impact remains unchanged in Q4.

Zacks | 1 year ago
The Long-Term Upside For Chemours Company After Q4 2024

The Long-Term Upside For Chemours Company After Q4 2024

I've been investing in Chemours for years, despite recent accounting irregularities and share price decline since before 2024. Chemours, a leader in the titanium dioxide sector, also excels in new refrigerants like Opteon due to regulatory changes. Despite recent poor returns, I remain confident in Chemours' fundamentals and long-term potential, especially after 4Q24.

Seekingalpha | 1 year ago
The Chemours Company (CC) Q4 2024 Earnings Call Transcript

The Chemours Company (CC) Q4 2024 Earnings Call Transcript

The Chemours Company (NYSE:CC ) Q4 2024 Earnings Conference Call February 18, 2025 8:00 AM ET Company Participants Brandon Ontjes - VP of IR Denise Dignam - President and CEO Shane Hostetter - SVP and CFO Conference Call Participants Arun Viswanathan - RBC Capital Markets Josh Spector - UBS Hassan Ahmed - Alembic Global Advisors John McNulty - BMO Vincent Andrews - Morgan Stanley John Roberts - Mizuho Laurence Alexander - Jefferies Jeff Zekauskas - JPMorgan Pete Osterland - Truist Operator Good morning. My name is Michelle, and I will be your conference operator today.

Seekingalpha | 1 year ago
Chemours (CC) Reports Q4 Earnings: What Key Metrics Have to Say

Chemours (CC) Reports Q4 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Chemours (CC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks | 1 year ago
Chemours (CC) Q4 Earnings Beat Estimates

Chemours (CC) Q4 Earnings Beat Estimates

Chemours (CC) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.31 per share a year ago.

Zacks | 1 year ago
Earnings Preview: Chemours (CC) Q4 Earnings Expected to Decline

Earnings Preview: Chemours (CC) Q4 Earnings Expected to Decline

Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 year ago
Chemours, Tronox And Westlake Will See Earnings Rebound In Chemical Sector Amid TiO2 Recovery And Margin Expansion: Analyst

Chemours, Tronox And Westlake Will See Earnings Rebound In Chemical Sector Amid TiO2 Recovery And Margin Expansion: Analyst

Truist Securities analyst Peter Osterland initiated coverage on several chemicals stocks ahead of earnings release.

Benzinga | 1 year ago
Loading...
Load More